News - Events
Algiax Pharmaceuticals Announces First Patient Enrolled in Phase IIa Multi-center Proof-of-Concept Study Evaluating AP-325 in Chronic Neuropathic Pain
DÜSSELDORF, Germany–(BUSINESS WIRE)–Algiax Pharmaceuticals, a clinical-stage biotechnology company focused on development of GABAA receptor modulators for neuropathic pain and other indications with unmet medical need, announced
Algiax Pharmaceuticals finalizes financing round and welcomes OCCIDENT and a German family office as new investors on board. DÜSSELDORF, Germany–(BUSINESS WIRE)–Algiax Pharmaceuticals, a clinical-stage biotechnology
Algiax Pharmaceuticals appoints Prof. Claudia Sommer and Dr. Klaus-Dieter Langner to join its Scientific Advisory Board
Clinical neuropathic pain expert Prof. Sommer and long-time pain pharma industry expert Dr. Langner to consult Algiax Pharmaceuticals in the development of AP-325 and further
Algiax Pharmaceuticals is a clinical-stage biotechnology company established in 2011.
It is dedicated to the discovery and development of innovative products to treat diseases with a high unmet medical need.
Algiax’ lead candidate AP-325 is a small-molecule GABAA receptor modulator in clinical development as a therapy for neuropathic pain.
Next to AP-325 Algiax has discovered novel GABAA receptor modulator compounds called Thioacrylamide (ThAc) derivatives. The company is advancing a selection of ThAcs derivatives from its discovery to preclinical characterization.
Dr. Ingo Lehrke
Dr. Guido Koopmans
Dr. Birgit Hasse
Head of CMS and Regulator Affairs
Finance and Transaction Advisor
Dr. Jürgen Schumacher
Prof. Dr. med.
Dr. Klaus-Dieter Langner
R & D Overview
Mrs. Martina Zmugg
Information pursuant to § 5 TMG
Algiax Pharmaceuticals GmbH
Commercial Register: HRB 23420
Registration Court: Wuppertal
Dr. Ingo Lehrke, Chief Executive Officer
Dr. Guido Koopmans, Chief Scientific Officer
Sales tax identification number according to § 27a of the Sales Tax Law: